Pembrolizumab in Patients with Tumors with High Tumor Mutational Burden: Results from the Targeted Agent and Profiling Utilization Registry Study

Herbert L. Duvivier, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eugene R. Ahn, Tareq Al Baghdadi, Ajjai S. Alva, Stephanie A. Dublis, Timothy L. Cannon, Carmen J. Calfa, Rui Li, Deepti Behl, Vi K. Chiu, Philip J. Gold, Alissa S. Marr, Kathryn F. Mileham, Steven Francis Powell, Jordi Rodon, Ramya Thota, Gina N. GranthamAbigail Gregory, Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

PURPOSEThe Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a pragmatic basket trial evaluating antitumor activity of approved targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from cohorts of patients with high tumor mutational burden (HTMB, defined as â ‰¥9 mutations per megabase) with advanced colorectal cancer (CRC) and other advanced cancers treated with pembrolizumab are reported.METHODSEligible patients were 18 years and older with measurable tumors and a lack of standard treatment options, an Eastern Cooperative Oncology Group performance status of 0-1, and adequate organ function. The primary end point was disease control (DC), defined as complete or partial response or stable disease (SD) of at least 16-weeks duration. For the CRC cohort, Simon's two-stage design with a null DC rate of 15% versus 35% (power = 0.85; α =.10) was used. Low accruing histology-specific cohorts were collapsed into one histology-pooled (HP) cohort. For the HP cohort, the null hypothesis of a DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was >15%. Secondary end points included objective response (OR), safety, progression-free survival, overall survival, duration of response, and duration of SD.RESULTSSeventy-seven patients with HTMB with CRC (n = 28) or advanced cancers (n = 49) were treated with pembrolizumab. For the CRC cohort, the DC rate was 31% (P =.04) and the OR rate was 11%. For the HP cohort, the DC rate was 45% (one-sided 90% CI, 35 to 100) and the OR rate was 26%. The null hypothesis of a 15% DC rate was rejected for both cohorts. Twelve of 77 patients experienced treatment-related grade 3 adverse events (AEs) or serious AEs, including two deaths.CONCLUSIONPembrolizumab demonstrated antitumor activity in pretreated patients with advanced cancers and HTMB.

Original languageEnglish (US)
Pages (from-to)5140-5150
Number of pages11
JournalJournal of Clinical Oncology
Volume41
Issue number33
DOIs
StatePublished - Nov 20 2023

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Pembrolizumab in Patients with Tumors with High Tumor Mutational Burden: Results from the Targeted Agent and Profiling Utilization Registry Study'. Together they form a unique fingerprint.

Cite this